Zhou Wei-Ying, Shi Yun, Wu Chao, Zhang Wei-Jun, Mao Xu-Hu, Guo Gang, Li Hai-Xia, Zou Quan-Ming
Department of Clinical Microbiology and Immunology, College of Medical Laboratory Science, The Third Military Medical University, Chongqing 400038, PR China.
Vaccine. 2009 Aug 6;27(36):5013-9. doi: 10.1016/j.vaccine.2009.05.009. Epub 2009 May 27.
Epitope vaccine is a promising option for therapeutic vaccination against Helicobacter pylori (H. pylori) infection. In this study, we constructed a multi-epitope vaccine with five epitopes and mucosal adjuvant E. coli heat-labile enterotoxin B subunit (LTB) named HUepi-LTB and evaluated its therapeutic effect against H. pylori infection in BALB/c mice model. HUepi-LTB containing three Th epitopes from UreB and two B cell epitopes from UreB and HpaA was constructed and expressed in E. coli. Oral therapeutic immunization with HUepi-LTB significantly decreased H. pylori colonization compared with oral immunization with PBS, and the protection was correlated with antigen-specific CD4+ T cells and IgG and mucosal IgA antibody responses. This multi-epitope vaccine may be a promising vaccine candidate that may help to control H. pylori infection.
表位疫苗是治疗幽门螺杆菌（H. pylori）感染的一种有前景的疫苗选择。在本研究中，我们构建了一种包含五个表位和黏膜佐剂大肠杆菌不耐热肠毒素B亚基（LTB）的多表位疫苗，命名为HUepi-LTB，并在BALB/c小鼠模型中评估了其对H. pylori感染的治疗效果。构建了包含来自尿素酶B（UreB）的三个Th表位以及来自UreB和HpaA的两个B细胞表位的HUepi-LTB，并在大肠杆菌中进行表达。与用磷酸盐缓冲盐水（PBS）口服免疫相比，用HUepi-LTB进行口服治疗性免疫显著降低了H. pylori的定植，并且这种保护作用与抗原特异性CD4+ T细胞以及IgG和黏膜IgA抗体反应相关。这种多表位疫苗可能是一种有前景的候选疫苗，有助于控制H. pylori感染。
